A
Alan Anthoney
Researcher at Leeds Teaching Hospitals NHS Trust
Publications - 103
Citations - 9304
Alan Anthoney is an academic researcher from Leeds Teaching Hospitals NHS Trust. The author has contributed to research in topics: Gemcitabine & Cancer. The author has an hindex of 27, co-authored 90 publications receiving 7203 citations. Previous affiliations of Alan Anthoney include University of Glasgow & University of Bradford.
Papers
More filters
Journal ArticleDOI
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
Juan Ignacio Valle,Harpreet Wasan,Daniel H. Palmer,David Cunningham,Alan Anthoney,Anthony Maraveyas,Srinivasan Madhusudan,Timothy Iveson,Sharon M. Hughes,Stephen P. Pereira,M Roughton,John Bridgewater +11 more
TL;DR: Cisplatin plus gemcitabine is an appropriate option for the treatment of patients with advanced biliary cancer and was associated with a significant survival advantage without the addition of substantial toxicity.
Journal ArticleDOI
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial
John P. Neoptolemos,John P. Neoptolemos,Daniel H. Palmer,Daniel H. Palmer,Paula Ghaneh,Eftychia E. Psarelli,Juan W. Valle,Christopher Halloran,Christopher Halloran,Olusola Olusesan Faluyi,Derek A. O'Reilly,David Cunningham,Jonathan Wadsley,Suzanne Darby,Tim Meyer,Roopinder Gillmore,Alan Anthoney,Pehr Lind,Bengt Glimelius,Stephen Falk,Jakob R. Izbicki,Gary Middleton,Sebastian Cummins,Paul Ross,Harpreet Wasan,Alec McDonald,Tom Crosby,Yuk Ting Ma,Kinnari Patel,David Sherriff,Rubin Soomal,David Borg,Sharmila Sothi,Pascal Hammel,Thilo Hackert,Richard J. Jackson,Markus W. Büchler +36 more
TL;DR: The adjuvant combination of gem citabine and capecitabine should be the new standard of care following resection for pancreatic ductal adenocarcinoma.
Journal ArticleDOI
Redefining the R1 resection in pancreatic cancer.
Caroline S. Verbeke,D. Leitch,Krishna V. Menon,Michael J. McMahon,P. J. Guillou,Alan Anthoney +5 more
TL;DR: The aim of this study was to assess the influence of standardized pathological examination on the reporting of RM status in pancreatic head adenocarcinoma.
Journal Article
Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial
John P. Neoptolemos,Malcolm J. Moore,Trevor Cox,Juan W. Valle,Daniel H. Palmer,Alec McDonald,Rodney William Carter,Niall C. Tebbutt,Christos Dervenis,D. Smith,Bengt Glimelius,Richard Charnley,François Lacaine,Scarfe Ag,Middleton,Alan Anthoney,Paula Ghaneh,Christopher Halloran,Markus M. Lerch,Attila Oláh,Charlotte L. Rawcliffe,Caroline S. Verbeke,Fiona Campbell,M.W. Büchler +23 more
TL;DR: Among patients with resected periampullary adenocarcinoma, adjuvant chemotherapy, compared with observation, was not associated with a significant survival Benefit in the primary analysis; however, multivariable analysis adjusting for prognostic variables demonstrated a statistically significant survival benefit associated with adjuant chemotherapy.
Journal ArticleDOI
Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.
John P. Neoptolemos,Malcolm J. Moore,Trevor Cox,Juan W. Valle,Daniel H. Palmer,A. C. McDonald,Ross Carter,Niall C. Tebbutt,Christos Dervenis,David Smith,Bengt Glimelius,Richard Charnley,François Lacaine,Andrew Scarfe,Mark R. Middleton,Alan Anthoney,Paula Ghaneh,Christopher Halloran,Markus M. Lerch,Attila Oláh,Charlotte L. Rawcliffe,Caroline S. Verbeke,Fiona Campbell,Markus W. Büchler +23 more
TL;DR: In this article, the hazard ratio for chemotherapy compared with observation was 0.75 (95% CI, 0.57-0.98; 2 = 1.33; P=.25).